Evidence map›Paper›PMID 40040875›Full record

ArticleJournal of the National Cancer Center2025

Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141].

Rong Li, Hongping Zhang, Qingshui Li, Guangwen Yuan, Yanjie Zhou, Rutie Yin, He Wang, Chunyan Wang, Yi Huang, Wei Wang and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Rong LiThe Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.
Hongping ZhangDepartment of Gynecologic, Yunnan Cancer Hospital, Kunming, China.
Qingshui LiDepartment of Gynecologic Oncology, Shandong Cancer Hospital, Jinan, China.
Guangwen YuanDepartment of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Yanjie ZhouDepartment of Gynecologic Oncology, Hunan Cancer Hospital, Changsha, China.
Rutie YinDepartment of Tumor Radiotherapy and Chemotherapy, West China Second University Hospital of Sichuan University, Chengdu, China.
He WangDepartment of Gynecologic, Guangxi Cancer Institute, Nanning, China.
Chunyan WangDepartment of Gynecologic Oncology, Liaoning Cancer Hospital, Shenyang, China.
Yi HuangDepartment of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China.
Wei WangThe Gynecologic Oncology Center, Peking Union Medical College Hospital, Beijing, China.
Xiaojian YanDepartment of Gynecologic, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Lingying WuDepartment of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Qi ZhouThe Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.jncc.2024.04.004.].

Identifiers

PMID40040875
PMCPMC11873657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.